More Clarity Pharmaceuticals Ltd. news
Clarity Pharmaceuticals Ltd.ASX: CU6

S&P DJI Announces March 2024 Quarterly Rebalance

Mar 1, 2024 at 6:24 AM EST · Issued by Clarity Pharmaceuticals Ltd.

Filed with ASX · Mar 1, 2024 at 6:24 AM EST · 8 pages · English

On 6ix: 6ix.com/news/sandp-dji-announces-march-2024-quarterly-rebalance-12

Clarity Pharmaceuticals Ltd. on 6ix

Earlier from Clarity Pharmaceuticals

  • Initial COBRA resultsFeb 14, 2024
  • First patient dosed in Phase III prostate cancer trialDec 21, 2023
  • Recruitment closes for a diagnostic Phase II trial in NETsDec 18, 2023
  • Phase III CLARIFY trial in prostate cancer commencesNov 29, 2023
  • undetectable PSA level with Cu-67 SAR-bisPSMANov 29, 2023

Later from Clarity Pharmaceuticals

  • Additional COBRA trial data resultsMar 5, 2024
  • Theranostic prostate cancer trial advances to multi-doseMar 15, 2024
  • First participant treated in the last dose escalation cohortMar 21, 2024
  • Trading HaltMar 24, 2024
  • Clarity launches $121 million equity raiseMar 25, 2024
All Clarity Pharmaceuticals news releases↗

Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.

Follow Clarity Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer